Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Attaining optimal glycemic targets in patients with type 2 diabetes is often hard and compromised by the shortcomings of the several treatments. Areas covered: When glycemic levels are not adequately controlled, an association of GLP-1 receptor agonists and insulin therapy can be adopted. In order to assess the benefit/risk profile of this combination therapy, a literature search of randomized clinical trials was performed.Eighteen trials matched the inclusion criteria. In 10 studies, GLP-1 receptor agonists were added on to an existing regimen, whereas insulin added to an existing GLP-1 receptor agonists regimen occurred in 2 studies. Six studies compared GLP-1 receptor agonists with short acting insulin as a treatment strategy to intensify basal insulin therapy. Expert opinion: Clinical trials herein reviewed demonstrated the safety and the efficacy of combining GLP-1 receptor agonists with basal insulin, with most studies showing equal or slightly superior efficacy, as compared with the addition of prandial insulin, associated with weight loss and less hypoglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Moreover, since the LEADER study [48] showed a reduction of cardiovascular risk, further studies could better delineate the cardiovascular safety profile of fixed combination of liraglutide.”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 3×
“Accordingly, in those patients on basal insulin with one or more oral agents, whose diabetes is still not controlled, current guidelines [6] suggest that the addition of a GLP-1 RA or mealtime insulin could be viewed as a logical escalation of the antidiabetic therapy.”
BackgroundInfluentialWriting Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e3182456d46 · Cited by 1,512
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“However, intensive insulin regimens are related to a higher risk of hypoglycemia and weight gain, both of them being related to worse long-term outcomes [9,10].”
BackgroundBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506 · cited 1×
“[27] conducted the first study in order to test whether exenatide (10 μg BID) reduced HbA1c levels more than placebo in patients already receiving insulin glargine alone or in combination with metformin or pioglitazone.”
BackgroundDungan, K. M., Povedano, S. T., Forst, T., González, J. G. G., Atisso, C., Sealls, W., & Fahrbach, J. L. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60976-4 · Cited by 486
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4127 · Cited by 412
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Pratley, R. E., Nauck, M. A., Barnett, A. H., Feinglos, M. N., Ovalle, F., Harman-Boehm, I., Ye, J., Scott, R., Johnson, S., Stewart, M., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70214-6 · Cited by 326
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 1×
“α-glucosidase inhibitors, and DPP-4 inhibitors and are comparable with basal insulin and biphasic insulin [12]; their use is also associated with low risk of hypoglycemia, weight loss [12], and modest reduction of blood pressure [13].”
BackgroundRiddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288 · cited 1×
“GetGoal-Duo L study [28] was a 24-week RCT in which 495 patients with established basal insulin therapy were randomized to lixisenatide 20 μg or placebo.”
Meier, J. J., Rosenstock, J., Hincelin-Méry, A., Roy-Duval, C., Delfolie, A., Coester, H.-V., Menge, B. A., Forst, T., & Kapitza, C. (2015) · Diabetes Care · doi:10.2337/dc14-1984 · Cited by 262
Glucagon-like peptide analogues for type 2 diabetes mellitus
Shyangdan, D. S., Royle, P., Clar, C., Sharma, P., Waugh, N., & Snaith, A. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006423.pub2 · Cited by 246 · cited 1×
“GLP-1 RAs are injectable antidiabetic drugs that have been proven to be effective in the treatment of T2DM [11].”
BackgroundLiu, S. ‐., Tu, Y. ‐., Chien, M. ‐., & Chien, K. ‐. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01606.x · Cited by 180 · cited 1×
“Sulfonylureas and insulin are associated with hypoglycemia and increased risk of weight gain [45]; thiazolidinediones are associated with several undesirable AEs, including edema, increased risk of heart failure, and fractures [46], whereas SGLT-2 inhibitors use may lead to an increased risk of genitourinary infection…”
BackgroundDeVries, J. H., Bain, S. C., Rodbard, H. W., Seufert, J., D’Alessio, D., Thomsen, A. B., Zychma, M., Rosenstock, J., & on behalf of the Liraglutide-Detemir Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1928 · Cited by 159 · cited 3×
“[27–36], whereas the opposite (insulin added to an existing GLP-1 RA regimen) occurred in 2 studies [37,38].”
BackgroundMethodThe FLAT-SUGAR Trial Investigators (2016) · Diabetes Care · doi:10.2337/dc15-2782 · Cited by 135
Cited by
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Giugliano, D., Longo, M., Caruso, P., Di Fraia, R., Scappaticcio, L., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Diabetes Care · doi:10.2337/dc20-2623 · Cited by 69
Self-citationHansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine · doi:10.1111/dme.14655 · Cited by 23
“Numbers of antidiabetic drugs were increased from [median (quartiles)] 1 [1,2] to 3 [2,3] among the GLP1RA naïve and from 1 [1,2] to 3 [2,3] among the GLP1RAexperienced with no statistical difference between groups.”
BackgroundAnatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
Self-citation
Metadata
- Authors
- Cimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2016-11-22
- Volume
- 15
- Issue
- sup2
- Pages
- 77-83
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2550818850
- Cited by
- 33
- References
- 17
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.